ArticleCirculation reports2025
Comparing Effects of Tafamidis in Controlling Left Ventricular and Left Atrial Strains in Patients With Wild-Type Transthyretin Amyloid Cardiomyopathy.
Article in Circulation reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Clinical Factors Related to Cardiac Conduction Disturbance in Patients With Wild-Type Transthyretin Amyloid Cardiomyopathy Undergoing Tafamidis Treatment.Circulation reports · 2026Article
- Differential Effects of Tafamidis on Cardiac Remodelling in Transthyretin Amyloid Cardiomyopathy: Evidence From Contemporary Imaging Data.European journal of clinical investigation · 2026Review
- Tafamidis in the Contemporary Management of Transthyretin Cardiac Amyloidosis: A Systematic Review.Journal of clinical medicine · 2026Review
- Association Between Severe Aortic Stenosis and Amyloid Deposition in the Myocardium of Patients With Wild-Type Transthyretin Cardiac Amyloidosis.Circulation reports · 2026Article
- Efficacy and Safety of Acoramidis in Japanese Adults With Symptomatic Transthyretin Amyloid Cardiomyopathy.Circulation reports · 2026Article
- Triplane Left Atrial Reservoir Strain in Cardiac Amyloidosis: A Comparative Study with Rhythm-Matched Controls.Clinics and practice · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Although tafamidis is used to treat patients with transthyretin amyloid cardiomyopathy (ATTR-CM), its specific effects on cardiac function remain unclear. Thus, this study aimed to investigate the effect of tafamidis on left atrial (LA) and left ventricular (LV) functions using speckle-tracking echocardiography after 1.5 years of treatment in patients with wild-type transthyretin amyloid cardiomyopathy (ATTRwt-CM). Methods and Results: We included 27 patients (mean age, 76 years) with ATTRwt-CM confirmed by biopsy. We analyzed LV and LA strains using 2-dimensional speckle-tracking echocardiography and compared these parameters before and after a 1.5-year follow up between 20 patients with and 7 patients without tafamidis treatment. Echocardiography speckle tracking examination showed no significant changes in global longitudinal strain (GLS) or LA reservoir strain (LASr) in patients with ATTRwt-CM after 1.5 years of tafamidis treatment. However, significant deterioration of GLS (-9.3 [-11, -7.4] to -8.0 [-9, -6.7]; P=0.0381) and LASr (11 [6, 16] to 6 [5, 11]; P=0.0074) were observed in patients with ATTRwt-CM without tafamidis. Conclusions: The LA and LV functions of patients with ATTRwt-CM treated with tafamidis were more favorable than those of untreated patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.